Parathyroid hormone may be a cancer promoter - An explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and Vitamin D

Medical Hypotheses

Volumn 54, Issue 3, 2000, Pages 475-482

  McCarty, M F ^a  

^a Nutrition 21   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN C; VITAMIN D;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; COLON CANCER; DIETARY INTAKE; HUMAN; HYPERTENSION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUN EXPOSURE; TUMOR PROMOTION; ULTRAVIOLET RADIATION;

EID: 0034075170     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0880     Document Type: Article

References (123)

1. Garland C. F., Garland F. C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 9:1980;227-231.
2. Garland C. F., Garland F. C., Gorham E. D. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr. 54:1991;193S-201S.
3. Emerson J. C., Weiss N. S. Colorectal cancer and solar radiation. Cancer Causes Control. 3:1992;95-99.
4. Gorham E. D., Garland C. F., Garland F. C. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Publ Hlth. 80:1989;96-100.
5. Garland F. C., Garland C. F., Gorham E. D., Young J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 19:1990;614-622.
6. Gorham E. D., Garland F. C., Garland C. F. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 19:1990;820-824.
7. Schwartz G. G., Hulka B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10:1990;1307-1312.
8. Hanchette C. L., Schwartz G. C. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 70:1992;2861-2869.
9. Lefkowitz E. S., Garland C. F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 23:1994;1133-1136.
10. Ainsleigh H. G. Beneficial effects of sun exposure on cancer mortality. Prev Med. 22:1993;132-140.
11. Garland C., Shekelle R. B., Barrett-Connor E. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. i:1985;307-309.
12. Garland C. F., Garland F. C., Shaw E. K. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. ii:1989;1176-1178.
13. Bostick R. M., Potter J. D., Sellers T. A. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The lowa Women's Health Study. Am J Epidemiol. 137:1993;1302-1317.
14. Martinez M. E., Giovannucci E. L., Colditz G. A. Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst. 88:1996;1375-1382.
15. Kearney J., Giovannucci E., Rimm E. B. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol. 143:1996;907-917.
16. Pritchard R. S., Baron J. A., Gerhardsson de Verdier M. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev. 5:1996;897-900.
17. Braun M. M., Helzlsouer K. J., Hollis B. W., Comstock G. W. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol. 142:1995;608-611.
18. Braun M. M., Helzlsouer K. J., Hollis B. W., Comstock G. W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control. 6:1995;235-239.
19. Gann P. H., Ma J., Hennekens C. H. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 5:1996;121-126.
20. Knekt P., Albanes D., Seppänen R. Dietary fat and risk of breast cancer. Am J Clin Nutr. 52:1990;903-908.
21. Knekt P., Järvinen R., Seppänen R. Intake of dairy products and the risk of breast cancer. Br J Cancer. 73:1996;687-691.
22. Newmark H. L., Wargovich M. J., Bruce W. R. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst. 72:1984;1323-1325.
23. Wargovich M. J., Lointier P. H. Calcium and vitamin D modulate mouse colon epithelial proliferation and growth characteristics of a human colon tumor cell line. Can J Physiol Pharmacol. 65:1987;472-477.
24. Zhang L., Bird R. P., Bruce W. R. Proliferative activity of murine mammary epithelium as affected by dietary fat and calcium. Cancer Res. 47:1987;4905-4908.
25. Pence B. C., Buddingh F. Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis. 9:1988;187-190.
26. Jacobson E. A., James K. A., Newmark H. L., Carroll K. K. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 49:1989;6300-6303.
27. Newmark H. L., Lipkin M. Calcium, vitamin D, and colon cancer. Cancer Res. 52:1992;2067s-2070s.
28. Pence B. C. Role of calcium in colon cancer prevention: experimental and clinical studies. Mutation Res. 290:1993;87-95.
29. Newmark H. L. Vitamin D adequacy: a possible relationship to breast cancer. American Institute for Cancer Research. Diet and Breast Cancer Molecular Mechanisms of Interactions. 1994;109-114 Plenum Press, New York.
30. Lans J. I., Jaszewski R., Arlow F. L. Supplemental calcium suppresses colonic mucosal ornithine decarboxylase activity in elderly patients with adenomatous polyps. Cancer Res. 51:1991;3416-3419.
31. Bostick R. M., Potter J. D., Fosdick L. Calcium and colorectal epithelial cell proliferation: a preliminary randomized, double-blinded, placebo-controlled clinical trial. J Natl Cancer Inst. 85:1993;132-141.
32. Lipkin M., Newmark H. Calcium and the prevention of colon cancer. J Cell Biochem. 22:1995;65-73.
33. 3receptors in established human cancer cell lines in culture. Cancer Res. 42:1982;1116-1119.
34. 3. Cancer Res. 47:1987;21-25.
35. 3in gynecologic neoplasms. Gynecol Oncol. 44:1992;131-136.
36. 3receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1993;1952-1960.
37. Anzano M. A., Smith J. M., Uskokovic M. R. 1α,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5331), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 54:1994;1653-1656.
38. Brenner R. V., Shabahang M., Schumaker L. M. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett. 92:1995;77-82.
39. Welsh J., Simboli-Campbell M., Narvaez C. J., Tenniswood M. Role of apoptosis in the growth inhibitory effects of vitamin D in MCF-7 cells. American Institute for Cancer Research, Diet and Cancer. Molecular Mechanisms of Interactions. 1994;45-52 Plenum Press, New York.
40. 3derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer. 61:1995;806-811.
41. Feldman D., Skowronski R. J., Peehl D. M. Vitamin D and prostate cancer. American Institute for Cancer Research, Diet and Cancer. Molecular Mechanisms of Interactions. 1994;53-63 Plenum Press, New York.
42. Chesney R. W., Zimmerman J., Hamstra A. Vitamin D metabolite concentrations in vitamin D deficiency. Are calcitriol levels normal? Am J Dis Child. 135:1981;1025-1028.
43. Norman, A. W. Vitamin D. Present Knowledge in Nutrition, 6th edn. 120, 129.
44. Takeuchi A., Okano T., Ishida Y., Kobayashi T. Effects of dietary vitamin D intake on plasma levels of parathyroid hormone and vitamin D metabolites in healthy Japanese. Mineral Electrolyte Metab. 21:1995;217-222.
45. Malabanan A., Veronikis I. E., Holick M. F. Redefining vitamin D insufficiency. Lancet. 351:1998;805-806.
46. Chapuy M. C., Arlot M. E., Duboeuf F. Vitamin D and calcium to prevent hip fractures in elderly women. N Engl J Med. 327:1992;1637-1642.
47. Dawson-Hughes B., Harris S. S., Krall E. A., Dallal G. E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 337:1997;670-676.
48. Canalis E., Centrella M., Burch W., McCarthy T. L. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest. 83:1989;60-65.
49. Umayahara Y., Ji C., Centrella M. CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem. 272:1997;31793-31800.
50. Thissen J. P., Ketelslegers J. M., Underwood L. E. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 15:1994;80-101.
51. Coxam V., Davicco M-J., Durand D. Parathyroid hormone and calcitonin may modulate hepatic IGF-I production in calves. Acta Endocrinol. 123:1990;471-475.
52. Coxam V., Davicco M-J., Durand D. The influence of parathyroid hormone-related protein on hepatic IGF-I production. Acta Endocrinol. 126:1992;430-433.
53. Cosman F., Shen V., Xie F. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Ann Int Med. 118:1993;337-343.
54. Johansson A. G., Baylink D. J., af Ekenstam E. Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion. Bone Min. 24:1994;25-31.
55. Guler H. P., Zapf J., Schmid C., Froesch E. R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol. 121:1989;753-758.
56. Grahnen A., Kastrup K., Heinrich U. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr. 82:1993;9-13.
57. Caverzasio J., Shigematsu T., Rizzoli R., Bonjour J-P. Potential role of IGF-1 in parathyroid hormone-related renal growth induced by high protein diet in uninephrectomized rats. Kidney Intl. 48:1995;33-38.
58. Díez J., Laviades C. Insulin-like growth factor-I and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens. 12:1994;S31-S36.
59. Morrone L. F., Di Paolo S., Logoluso F. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation. 64:1997;913-918.
60. McCarty M. F. ACE inhibitors may impede promotion and progression of cancer. Submitted for publication, 1998.
61. Charest R., Prpic V., Exton J. H., Blackmore P. F. Stimulation of inositol trisphosphate formation in hepatocytes by vasopressin, adrenaline and angiotensin II and its relationship to changes in cytosolic free Ca2+. Biochem J. 227:1985;79-90.
62. Garcia-Sainz J. A., Macias-Silva M. Angiotensin II stimulates phosphoinositide turnover and phosphorylase through AII-1 receptors in isolated rat hepatocytes. Biochem Biophys Res Comm. 172:1990;780-785.
63. Gutowski S., Smrcka A., Nowak L. Antibodies to the alpha q subfamily of guanine nucleotide-binding regulatory protein alpha subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones. J Biol Chem. 266:1991;20519-20524.
64. Inagami T., Guo D. F., Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens. 12:1994;S83-S94.
65. Wang C., Jayadev S., Escobedo J. A. Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J Biol Chem. 270:1995;16677-16682.
66. Tollet P., Legraverend C., Gustafsson J. A., Mode A. A role for protein kinases in the growth hormone regulation of cytochrome P4502C12 and insulin-like growth factor-I messenger RNA expression in primary adult rat hepatocytes. Mol Endocrinol. 5:1991;1351-1358.
67. Mine T., Kojima I., Ogata E. Calcium rather than cyclic AMP is an intracellular messenger of parathyroid hormone action on glycogen metabolism in isolated rat hepatocytes. Biochem J. 258:1989;889-894.
68. Michnowska M., Smogorzewski M., Klin M. Effects of parathyroid hormone on hepatocyte pHi and Na(+)-H+ exchanger activity. Am J Nephrol. 16:1996;431-441.
69. Offermanns S., Iida-Klein A., Segre G. V., Simon M. I. G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells. Mol Endocrinol. 10:1996;566-574.
70. Iida-Klein A., Guo J., Takemura M. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J Biol Chem. 272:1997;6882-6889.
71. Sperling R. I., Benincaso A. I., Knoell C. T. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest. 91:1993;651-660.
72. McCarty M. F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses. 46:1996;191-221.
73. Bhathena S. J., Berlin E., Judd J. T. Effects of omega 3 fatty acids and vitamin E on hormones involved in carbohydrate and lipid metabolism in men. Am J Clin Nutr. 54:1991;684-688.
74. Landin-Wilhelmsen K., Wilhelmsen L., Lappas G. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol. 41:1994;351-357.
75. McCarty M. F. Vegan proteins may reduce risk for cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Submitted for publication, 1998.
76. Broadus A. E., Mangin M., Ikeda K. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med. 319:1988;556-563.
77. Muff R., Born W., Kaufmann M., Fischer J. A. Parathyroid hormone and parathyroid hormone-related protein receptor update. Mol Cell Endocrinol. 100:1994;35-38.
78. Alcantara A., Montalvo-Figueroa J. A., Toro S., Aguilo F. An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide. P R Health Sci J. 16:1997;15-22.
79. Fujino T., Watanabe T., Yamaguchi K. The development of hypercalcemia in a patient with an ovarian tumor producing parathyroid hormone-related protein. Cancer. 70:1992;2845-2850.
80. Kremer R., Shustik C., Tabak T. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med. 100:1996;406-411.
81. Birch M. A., Carron J. A., Scott M. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer. 72:1995;90-95.
82. Carron J. A., Fraser W. D., Gallagher J. A. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer. 76:1997;1095-1098.
83. Downey S. E., Hoyland J., Freemont A. J. Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J Pathol. 183:1997;212-217.
84. Luparello C., Birch M. A., Gallagher J. A., Burtis W. J. Clonal heterogeneity of the growth and invasive response of a human breast carcinoma cell line to parathyroid hormone-related peptide fragments. Carcinogenesis. 18:1997;23-29.
85. Bowcott M., Ratcliffe W. A., Hill-Wilson G., Bundred N. J. Parathyroid hormone-related protein is a growth factor for prostate cancer. Br J Surgery. 81:1994;767-768.
86. Iwamura M., Wu G., Abrahamsson P-A. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology. 43:1994;675-679.
87. Peehl D. M., Edgar M. G., Cramer S. D., Deftos L. J. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate. 31:1997;47-52.
88. Burton P. B. J., Knight D. E. Parathyroid hormone-related peptide can regulate the growth of human lung cancer cells, and may form part of an autocrine TGF-α loop. FEBS Lett. 305:1992;228-232.
89. Tomei L. D., Kanter P., Wenner C. E. Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem Biophys Res Comm. 155:1988;324-331.
90. McConkey D. J., Hartzell P., Jondal M., Orrenius S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem. 264:1989;13399-13402.
91. Wright S. C., Zhong J., Larrick J. W. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J. 8:1994;654-660.
92. Gopalakrishna R., Barsky S. H. Tumor promoter-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci. 85:1988;612-616.
93. Bonfil R. D., Momiki S., Fridman R. Enhancement of the invasive ability of a transformed human bronchial epithelial cell line by 12- O -tetradecanoylphorbol-13-acetate and diacylglycerol. Carcinogenesis. 10:1989;2335-2338.
94. Mackay A. R., Ballin M., Pelina M. D. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis. 12:1992;168-184.
95. Wysolmerski J. J., McCaughern-Carucci J. F., Daifotis A. G. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development. 121:1995;3539-3547.
96. Kremer R., Karaplis A. C., Henderson J. Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J Clin Invest. 87:1991;884-893.
97. Kremer R., Sebag M., Champigny C. Identification and characterization of 1,25-dihydroxyvitamin D3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene. J Biol Chem. 271:1996;16310-16316.
98. Falzon M. DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression. Mol Endocrinol. 10:1996;672-681.
99. Henderson J., Sebag M., Rhim J. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res. 51:1991;6521-6528.
100. Liu B., Goltzman D., Rabbani S. A. Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. Endocrinology. 132:1993;1658-1664.
101. Inoue D., Matsumoto T., Ogata E., Ikeda K. 22-oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J Biol Chem. 268:1993;16730-16736.
102. Endo K., Ichikawa F., Uchiyama Y. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J Biol Chem. 269:1994;32693-32699.
103. Yu J., Papavasiliou V., Rhim J. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anti-cancer Drugs. 6:1995;101-108.
104. Falzon M. The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression. Mol Cell Endocrinol. 127:1997;99-108.
105. Haq M., Kremer R., Goltzman D., Rabbani S. A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest. 91:1993;2416-2422.
106. Titus L., Jackson E., Nanes M. S. 1,25-dihydroxyvitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors: relationship to adenylate cyclase activation. J Bone Min Res. 6:1991;631-637.
107. Xie L. Y., Leung A., Segre G. V. Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. Am J Physiol. 270:1996;E654-E660.
108. Sebag M., Henderson J., Goltzman D., Kremer R. Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro. Am J Physiol. 267:1994;C723-C730.
109. Farr H. W., Fahey T. J. Jr, Nash A. G., Farr C. M. Primary hyperparathyroidism and cancer. Am J Surgery. 126:1973;539-543.
110. Allen L. H., Oddoye E. A., Margen S. Protein-induced hypercalciuria: a longer term study. Am J Clin Nutr. 32:1979;741-749.
111. Whiting S. J., Draper H. H. The role of sulfate in the calciuria of high protein diets in adult rats. J Nutr. 110:1980;212-222.
112. Hu J.-F., Zhao X.-H., Parpia B., Campbell T. C. Dietary intakes and urinary excretion of calcium and acids: a cross-sectional study of women in China. Am J Clin Nutr. 58:1993;398-406.
113. Zarkadas M., Gougeon-Reyburn R., Marless E. B. Sodium chloride supplementation and urinary calcium excretion in postmenopausal women. Am J Clin Nutr. 50:1989;1088-1094.
114. Nordin B. E. C., Need A. G., Morris H. A., Horowitz M. The nature and significance of the relationship between urinary sodium and urinary calcium in women. J Nutr. 123:1993;1615-1622.
115. Cappuccio F. P., Blackwood A., Sagnella G. A. Association between extra-cellular volume expansion and urinary calcium excretion in normal humans. J Hypertens. 11:1993;S196-S197.
116. MacGregor G. A., Cappuccio F. P. The kidney and essential hypertension: a link to osteoporosis? J Hypertens. 11:1993;781-785.
117. Stamler J. The INTERSALT study: background, methods, findings, and implications. Am J Clin Nutr. 65:1997;626S-642S.
118. McCarron D. A., Pingree P. A., Rubin R. J. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension. 2:1980;162-168.
119. Strazzullo P., Nunziata V., Cirillo M. Abnormalities of calcium metabolism in essential hypertension. Clin Sci. 65:1983;137-141.
120. Hamet P. Cancer and hypertension. An unresolved issue. Hypertension. 28:1996;321-324.
121. Khaw K.-T., Barrett-Connor E. Systolic blood pressure and cancer mortality in an elderly population. Am J Epidemiol. 120:1984;550-558.
122. Wachman A., Bernstein D. S. Diet and osteoporosis. Lancet. i:1968;958-959.
123. Robbins J. May All Be Fed. Diet for a New World. 1992.